New cholesterol drug inclisiran tracked in belgian heart patients

NCT ID NCT05726838

Ongoing Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study follows 600 Belgian adults with atherosclerotic cardiovascular disease who are prescribed inclisiran, a cholesterol-lowering injection, alongside their usual medications. Researchers will measure how much LDL cholesterol drops and how many patients reach their target levels in real-life conditions. The goal is to see if inclisiran works as well outside clinical trials as it does in them.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Inclisiran (a cholesterol-lowering injection)
What this could lead to: If successful, this study could confirm that inclisiran works well in everyday practice to help heart disease patients reach their LDL cholesterol goals.
What could go wrong: This is an observational registry, not a controlled trial, so results may be influenced by patient selection or other factors. It does not test a new treatment, only monitors existing use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATHEROSCLEROTIC CARDIOVASCULAR DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atherosclerosis atherosclerotic cardiovascular disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATHEROSCLEROTIC CARDIOVASCULAR DISEASE

More trials for these conditions

Other studies related to the condition(s) this trial covers.